NEW YORK (Reuters Health) – Among men who’ve had a negative prostate biopsy, the velocity of increasing prostate specific antigen (PSA) levels is not helpful in deciding whether…
NEW YORK (Reuters Health) – Patients with localized prostate cancer can be treated successfully with high-intensity focused ultrasound (HIFU), with results comparable to those expected with external-beam radiation…
NEW YORK (Reuters Health) – For locally advanced and metastatic prostate cancer, the best timing and duration of androgen-deprivation therapy (ADT) is unclear. Now, a systematic review suggests…
NEW YORK (Reuters Health) – Mounting evidence suggests that preoperative prostate specific antigen (PSA) kinetics are a poor marker of disease progression. During active surveillance for low-risk, low-volume…
NEW YORK (Reuters Health) – Prostate specific antigen (PSA) doubling time as measured before radical prostatectomy does not predict biochemical progression after surgery, according to a report in…
NEW YORK (Reuters Health) – Treatment with dutasteride reduces incident prostate cancers in men with high prostate specific antigen (PSA) levels, according to a report in The New…
NEW YORK (Reuters Health) – Androgen suppression therapy – and its attendant side effects — may not be necessary for patients with intermediate-risk prostate cancer treated with combination…
NEW YORK (Reuters Health) – For men with hot flushes from androgen suppression for prostate cancer, medroxyprogesterone appears to be the best option for relief, according to a…
NEW YORK (Reuters Health) – Contrary to previous assertions, low total cholesterol is not a cause of cancer, two separate studies show. Furthermore, a lower total cholesterol level…
NEW YORK (Reuters Health) – In detecting prostate cancer, no single prostate specific antigen (PSA) cut-off value achieves the likelihood ratios usually required of a screening test, according…